vs
Side-by-side financial comparison of PETMED EXPRESS INC (PETS) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $40.7M, roughly 1.4× PETMED EXPRESS INC). PETMED EXPRESS INC runs the higher net margin — -26.0% vs -83.0%, a 57.0% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs -23.3%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs -20.9%).
PetMed Express, Inc., also known as PetMeds, is an online pet pharmacy based in the United States. It is publicly traded and sells prescription and non-prescription pet medication.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
PETS vs RYTM — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $40.7M | $57.3M |
| Net Profit | $-10.6M | $-47.5M |
| Gross Margin | 23.3% | 91.6% |
| Operating Margin | -25.7% | -82.2% |
| Net Margin | -26.0% | -83.0% |
| Revenue YoY | -23.3% | 36.9% |
| Net Profit YoY | -1392.6% | -9.6% |
| EPS (diluted) | $-0.50 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $40.7M | $57.3M | ||
| Q3 25 | $44.4M | $51.3M | ||
| Q2 25 | $51.2M | $48.5M | ||
| Q1 25 | $50.8M | $32.7M | ||
| Q4 24 | $52.0M | $41.8M | ||
| Q3 24 | $58.0M | $33.3M | ||
| Q2 24 | $66.2M | $29.1M | ||
| Q1 24 | $65.1M | $26.0M |
| Q4 25 | $-10.6M | $-47.5M | ||
| Q3 25 | $-8.5M | $-52.9M | ||
| Q2 25 | $-34.2M | $-46.6M | ||
| Q1 25 | $-11.6M | $-49.5M | ||
| Q4 24 | $-707.0K | $-43.3M | ||
| Q3 24 | $2.3M | $-43.6M | ||
| Q2 24 | $3.8M | $-32.3M | ||
| Q1 24 | $-5.0M | $-141.4M |
| Q4 25 | 23.3% | 91.6% | ||
| Q3 25 | 28.0% | 89.3% | ||
| Q2 25 | 28.1% | 88.6% | ||
| Q1 25 | 29.9% | 88.8% | ||
| Q4 24 | 31.0% | 90.9% | ||
| Q3 24 | 32.3% | 88.5% | ||
| Q2 24 | 28.8% | 89.9% | ||
| Q1 24 | 29.3% | 89.2% |
| Q4 25 | -25.7% | -82.2% | ||
| Q3 25 | -18.9% | -102.6% | ||
| Q2 25 | -66.7% | -93.4% | ||
| Q1 25 | -11.9% | -143.7% | ||
| Q4 24 | -0.9% | -98.6% | ||
| Q3 24 | 1.0% | -132.0% | ||
| Q2 24 | 6.6% | -139.2% | ||
| Q1 24 | -5.9% | -538.7% |
| Q4 25 | -26.0% | -83.0% | ||
| Q3 25 | -19.2% | -103.1% | ||
| Q2 25 | -66.7% | -96.1% | ||
| Q1 25 | -22.9% | -151.4% | ||
| Q4 24 | -1.4% | -103.6% | ||
| Q3 24 | 4.0% | -131.2% | ||
| Q2 24 | 5.7% | -110.9% | ||
| Q1 24 | -7.7% | -544.4% |
| Q4 25 | $-0.50 | $-0.73 | ||
| Q3 25 | $-0.41 | $-0.82 | ||
| Q2 25 | $-1.65 | $-0.75 | ||
| Q1 25 | $-0.56 | $-0.81 | ||
| Q4 24 | $-0.03 | $-0.71 | ||
| Q3 24 | $0.11 | $-0.73 | ||
| Q2 24 | $0.18 | $-0.55 | ||
| Q1 24 | $-0.24 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $26.9M | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $32.8M | $139.1M |
| Total Assets | $88.0M | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $26.9M | $388.9M | ||
| Q3 25 | $36.1M | $416.1M | ||
| Q2 25 | $41.1M | $291.0M | ||
| Q1 25 | $54.7M | $314.5M | ||
| Q4 24 | $50.1M | $320.6M | ||
| Q3 24 | $52.0M | $298.4M | ||
| Q2 24 | $46.0M | $319.1M | ||
| Q1 24 | $55.3M | $201.2M |
| Q4 25 | $32.8M | $139.1M | ||
| Q3 25 | $43.1M | $148.8M | ||
| Q2 25 | $51.5M | $-11.9M | ||
| Q1 25 | $85.1M | $18.9M | ||
| Q4 24 | $96.2M | $21.7M | ||
| Q3 24 | $96.4M | $11.2M | ||
| Q2 24 | $93.5M | $39.3M | ||
| Q1 24 | $96.7M | $61.6M |
| Q4 25 | $88.0M | $480.2M | ||
| Q3 25 | $100.3M | $506.9M | ||
| Q2 25 | $109.8M | $372.7M | ||
| Q1 25 | $148.7M | $386.7M | ||
| Q4 24 | $144.8M | $392.3M | ||
| Q3 24 | $146.0M | $363.6M | ||
| Q2 24 | $152.7M | $381.8M | ||
| Q1 24 | $169.9M | $258.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-9.2M | $-25.4M |
| Free Cash FlowOCF − Capex | $-9.2M | — |
| FCF MarginFCF / Revenue | -22.7% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-23.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-9.2M | $-25.4M | ||
| Q3 25 | $-2.2M | $-26.6M | ||
| Q2 25 | $-12.3M | $-23.3M | ||
| Q1 25 | $7.0M | $-40.4M | ||
| Q4 24 | $-1.2M | $-18.8M | ||
| Q3 24 | $7.4M | $-25.2M | ||
| Q2 24 | $-8.5M | $-29.1M | ||
| Q1 24 | $7.1M | $-40.7M |
| Q4 25 | $-9.2M | — | ||
| Q3 25 | $-4.8M | — | ||
| Q2 25 | $-13.6M | — | ||
| Q1 25 | $4.6M | — | ||
| Q4 24 | $-1.9M | — | ||
| Q3 24 | $6.1M | — | ||
| Q2 24 | $-9.2M | — | ||
| Q1 24 | $5.9M | — |
| Q4 25 | -22.7% | — | ||
| Q3 25 | -10.8% | — | ||
| Q2 25 | -26.5% | — | ||
| Q1 25 | 9.1% | — | ||
| Q4 24 | -3.7% | — | ||
| Q3 24 | 10.6% | — | ||
| Q2 24 | -13.9% | — | ||
| Q1 24 | 9.0% | — |
| Q4 25 | 0.1% | — | ||
| Q3 25 | 5.9% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | 4.7% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | 1.9% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.18× | — | ||
| Q2 24 | -2.27× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PETS
| Reorder | $34.0M | 84% |
| New Order | $5.0M | 12% |
| Membership Fees | $1.6M | 4% |
RYTM
Segment breakdown not available.
